Description:
For collaboration partners requiring fully human antibodies directed against their targets for further development as therapeutics, MorphoSys provides highly optimized antibodies according to its partners’ pre-defined specifications, including full in vitro profiling of biological activities. In return, MorphoSys receives R&D funding, licensing and success payments, development milestones, and royalties on end products. MorphoSys is currently developing therapeutic antibodies with leading pharmaceutical companies such as Bayer Schering Pharma, Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche.